Institutional and Insider Ownership
64.2% of AB Corporate Bond ETF shares are held by institutional investors. Comparatively, 0.1% of ProMetic Life Sciences shares are held by institutional investors. 58.2% of AB Corporate Bond ETF shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares AB Corporate Bond ETF and ProMetic Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AB Corporate Bond ETF | N/A | -104.96% | -60.03% |
| ProMetic Life Sciences | -894.02% | -3,350.55% | -67.76% |
Valuation and Earnings
This table compares AB Corporate Bond ETF and ProMetic Life Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AB Corporate Bond ETF | $12,059.00 | 2,344.47 | -$8.09 million | ($1.68) | -21.04 |
| ProMetic Life Sciences | $36.55 million | 3.49 | -$150.73 million | N/A | N/A |
AB Corporate Bond ETF has higher earnings, but lower revenue than ProMetic Life Sciences.
Volatility and Risk
AB Corporate Bond ETF has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, indicating that its share price is 146% more volatile than the S&P 500.
Summary
AB Corporate Bond ETF beats ProMetic Life Sciences on 7 of the 9 factors compared between the two stocks.
About AB Corporate Bond ETF
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
About ProMetic Life Sciences
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Receive News & Ratings for AB Corporate Bond ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AB Corporate Bond ETF and related companies with MarketBeat.com's FREE daily email newsletter.
